Treatment of higher-risk myelodysplastic syndromes

Bilal K. Siddiqui, Muhammad A. Jadoon, Hamid Sayar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The term higher-risk is used arbitrarily in clinical practice to indicate more advanced stages of myelodysplastic syndromes (MDS). The intermediate-1 and high risk groups under the International Prognostic Scoring System (IPSS) are typically considered as higher-risk disease; while with the revised IPSS (IPSS-R), the high and very high risk groups would be under the category of higher-risk disease. Treatments considered for this group of patients are usually different to, and more aggressive than those offered for the lower-risk disease. In addition, sometimes under specific circumstances, patients with lower-risk disease are treated with such aggressive therapies. This chapter will provide a comprehensive review of management strategies for higher-risk MDS. A discussion regarding logical consideration of more aggressive therapies in lower-risk disease as well as choice of therapy in higher-risk patients will be offered. The chapter will also review clinically relevant details of agents and regimens used in the treatment of higher-risk MDS. Moreover, extensive description of clinical trials and available data on specific agents used in this setting will be provided.

Original languageEnglish
Title of host publicationMyelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy
PublisherNova Science Publishers, Inc.
Pages247-274
Number of pages28
ISBN (Print)9781624175749
StatePublished - Jan 2013

Fingerprint

Myelodysplastic Syndromes
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Siddiqui, B. K., Jadoon, M. A., & Sayar, H. (2013). Treatment of higher-risk myelodysplastic syndromes. In Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy (pp. 247-274). Nova Science Publishers, Inc..

Treatment of higher-risk myelodysplastic syndromes. / Siddiqui, Bilal K.; Jadoon, Muhammad A.; Sayar, Hamid.

Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc., 2013. p. 247-274.

Research output: Chapter in Book/Report/Conference proceedingChapter

Siddiqui, BK, Jadoon, MA & Sayar, H 2013, Treatment of higher-risk myelodysplastic syndromes. in Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc., pp. 247-274.
Siddiqui BK, Jadoon MA, Sayar H. Treatment of higher-risk myelodysplastic syndromes. In Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc. 2013. p. 247-274
Siddiqui, Bilal K. ; Jadoon, Muhammad A. ; Sayar, Hamid. / Treatment of higher-risk myelodysplastic syndromes. Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc., 2013. pp. 247-274
@inbook{ac1d9aaa7c40481dab9fe52367bfd0ec,
title = "Treatment of higher-risk myelodysplastic syndromes",
abstract = "The term higher-risk is used arbitrarily in clinical practice to indicate more advanced stages of myelodysplastic syndromes (MDS). The intermediate-1 and high risk groups under the International Prognostic Scoring System (IPSS) are typically considered as higher-risk disease; while with the revised IPSS (IPSS-R), the high and very high risk groups would be under the category of higher-risk disease. Treatments considered for this group of patients are usually different to, and more aggressive than those offered for the lower-risk disease. In addition, sometimes under specific circumstances, patients with lower-risk disease are treated with such aggressive therapies. This chapter will provide a comprehensive review of management strategies for higher-risk MDS. A discussion regarding logical consideration of more aggressive therapies in lower-risk disease as well as choice of therapy in higher-risk patients will be offered. The chapter will also review clinically relevant details of agents and regimens used in the treatment of higher-risk MDS. Moreover, extensive description of clinical trials and available data on specific agents used in this setting will be provided.",
author = "Siddiqui, {Bilal K.} and Jadoon, {Muhammad A.} and Hamid Sayar",
year = "2013",
month = "1",
language = "English",
isbn = "9781624175749",
pages = "247--274",
booktitle = "Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Treatment of higher-risk myelodysplastic syndromes

AU - Siddiqui, Bilal K.

AU - Jadoon, Muhammad A.

AU - Sayar, Hamid

PY - 2013/1

Y1 - 2013/1

N2 - The term higher-risk is used arbitrarily in clinical practice to indicate more advanced stages of myelodysplastic syndromes (MDS). The intermediate-1 and high risk groups under the International Prognostic Scoring System (IPSS) are typically considered as higher-risk disease; while with the revised IPSS (IPSS-R), the high and very high risk groups would be under the category of higher-risk disease. Treatments considered for this group of patients are usually different to, and more aggressive than those offered for the lower-risk disease. In addition, sometimes under specific circumstances, patients with lower-risk disease are treated with such aggressive therapies. This chapter will provide a comprehensive review of management strategies for higher-risk MDS. A discussion regarding logical consideration of more aggressive therapies in lower-risk disease as well as choice of therapy in higher-risk patients will be offered. The chapter will also review clinically relevant details of agents and regimens used in the treatment of higher-risk MDS. Moreover, extensive description of clinical trials and available data on specific agents used in this setting will be provided.

AB - The term higher-risk is used arbitrarily in clinical practice to indicate more advanced stages of myelodysplastic syndromes (MDS). The intermediate-1 and high risk groups under the International Prognostic Scoring System (IPSS) are typically considered as higher-risk disease; while with the revised IPSS (IPSS-R), the high and very high risk groups would be under the category of higher-risk disease. Treatments considered for this group of patients are usually different to, and more aggressive than those offered for the lower-risk disease. In addition, sometimes under specific circumstances, patients with lower-risk disease are treated with such aggressive therapies. This chapter will provide a comprehensive review of management strategies for higher-risk MDS. A discussion regarding logical consideration of more aggressive therapies in lower-risk disease as well as choice of therapy in higher-risk patients will be offered. The chapter will also review clinically relevant details of agents and regimens used in the treatment of higher-risk MDS. Moreover, extensive description of clinical trials and available data on specific agents used in this setting will be provided.

UR - http://www.scopus.com/inward/record.url?scp=84895214931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895214931&partnerID=8YFLogxK

M3 - Chapter

SN - 9781624175749

SP - 247

EP - 274

BT - Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy

PB - Nova Science Publishers, Inc.

ER -